Devon Labs is an innovative company created with the objective of improving the quality of life of patients and their carers, through commercializing our own portfolio of products. We focus on niche markets with the aim of resolving unmet needs and developing a new focus supported by digital technologies that complement conventional treatment.
Devon Labs originated from Devon Farmacéutica, a Spanish company created in 2003.
Continuous growth for more than 15 years in Spain and other parts of Europe.
ProStrakan is acquired by Kyowa Hakko Kirin, a Japanese company with a global presence.
In October 2020 an agreement was signed with Sandoz (Group Novartis) for the launch of four products in the areas of Oncology and Pain.
A team that has worked together for more than ten years, with a proven track record of setting up companies and business units, as well as launching products in diverse therapeutic areas.
